HepaSphere's targeted chemo:
This article was originally published in Clinica
Executive Summary
BioSphere Medical has CE-marked its doxorubicin-impregnated microspheres for sale in Europe under the name HepaSphere. The product will be used for the transarterial chemoembolisation (TACE) of hepatocellular carcinoma (HCC). As a condition of the approval, BioSphere will conduct a multicentre European post-marketing registry in 100 patients. Standard TACE involves injection of a concentrated dose of a chemotherapeutic, such as doxorubicin, directly into the blood vessels supplying a tumour, followed by the infusion of an embolic agent into these blood vessels, thus blocking its blood supply. The blocked vessels force the chemotherapeutic into direct contact with the tumour and minimise side-effects. TACE using HepaSphere loaded with doxorubicin further concentrates the chemotherapeutic effect by embolising the target tissue better and delivering the drug over an extended time frame, Rockland, Massachusetts-based BioSphere claims.
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.